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ABSTRACT 
 
Putative cannabinoid receptor 2 (CB2)-selective agonists were identified from a library of 
commercially available compounds via inhibition of cAMP accumulation in high 
throughput screening. Binding affinity and receptor subtype selectivity were assessed 
using heterologous competition binding assays against the known cannabinoid 
orthosteric ligand CP55940. Test compounds ASX0152383 and CSC003141 
preferentially bound to CB2, with no detection of binding to CB1 up to 1 µM. CMB038865 
exhibited nearly 100-fold selectivity for CB1 over CB2, while CZ000026 bound non-
preferentially to both receptors in the low micromolar range. To determine the extent of G 
protein coupling, GTP!S binding assays were performed. Dose-dependent increases in 
binding of the nonhydrolyzable GTP analog to G" subunits were induced by all test 
compounds. G protein-mediated MAPK signaling downstream of high affinity compounds 
was assessed by measuring ERK1/2 phosphorylation in the presence and absence of 
pertussis toxin (PTX). Activation induced by ASX015283 agonism at CB2 resulted in ERK 
1/2 phosphorylation which was abrogated by PTX, indicating Gi/o protein-dependence.  
Interestingly, CMB038865 agonism at CB1 resulted in low levels of ERK phosphorylation 
and signaling was not abrogated by PTX.  However, CMB038665 agonism at CB2 resulted 
in robust levels of ERK phosphorylation in a PTX-sensitive manner, indicative of Gi/o 
protein-dependent signaling. These results indicate CMB038865 is a partially selective 
CB1 agonist potentially biased towards G protein signaling pathways, while ASX015283 
and CSC003141 are CB2-selective agonists that may possess therapeutic potential for 
the treatment of chronic pain and inflammation without the psychoactive effects 
concomitant with activation of CB1 receptors in the central nervous system. 
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1. BACKGROUND AND SIGNIFICANCE 
 
1.1 G Protein-Coupled Receptors and Clinical Significance 
G protein-coupled receptors (GPCRs) are seven-transmembrane (7-TM) domain proteins 
that are abundant and a physiologically instrumental receptor superfamily in the human 
body. Upon ligand binding, GPCRs transduce extracellular signals across the biological 
membrane to elicit cellular responses. GPCR ligands are diverse in nature and include 
photons, odorant molecules, growth factors, hormones, peptides, small molecules, and 
neurotransmitters. This multiplicity of ligands facilitates the diverse role of GPCRs in 
significant physiological processes including hormone signaling, homeostatic 
mechanisms, behavioral modulation, mediation of the senses including vision, gustation, 
olfaction, autonomic nervous system transmission and immune regulation. This diversity 
leads to critical involvement in numerous pathologies, and GPCRs are thus an attractive 
target for drug discovery (Rosenbaum et al., 2009).  
 
1.2 GPCR Structure 
GPCRs are divided into six subclasses (A-F) based on functional similarity and sequence 
homology. Structural commonalities across GPCR classes include the characteristic 7- 
TM "-helices consisting of approximately 25-35 predominantly hydrophobic amino acid 
residues each, an extracellular amino terminus, and an intracellular carboxyl terminus 
(Gilchrist, 2010). In addition, three 
intracellular (IC1-3) and three 
extracellular (EC1-3) loops alternately 
connect the helices.  Particularly in the 
case of class A GPCRs, which are 
exemplified by the prototypical 
rhodopsin, the extracellular loops and 
the top portions of the TM domains are 
thought to form pockets to which 
ligands bind the receptor while the 
Figure 1. Structural schematic of a G protein-coupled 
receptor in the inactivated GDP-bound state.  
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intracellular regions are thought to interact with downstream effectors including guanine 
nucleotide-binding proteins (heterotrimeric G proteins) and #-arrestins (Wootten et al., 
2013).  
 
1.3 GPCR Signal Transduction  
Upon ligand binding, the GPCR undergoes a conformational change resulting in structural 
rearrangement of the "-helices and receptor activation. Intracellular heterotrimeric G 
proteins consisting of G", G# and G! subunits also become activated. This activation 
triggers the dissociation of guanine diphosphate (GDP), which is bound to the inactive G 
protein, to facilitate the binding of guanine triphosphate (GTP) to the G" subunit (the 
active state). The G" subunit bound to GTP dissociates from the #! complex and can 
subsequently initiate downstream signaling events. For a comprehensive review on 
GPCR signaling, see Whalen et al., 2011. 
 
1.4 The Cannabinoid Receptors 
The cannabinoid receptors are among the class A rhodopsin-like GPCR subfamily. There 
are two canonical cannabinoid receptors, cannabinoid receptor one (CB1) and 
cannabinoid receptor two (CB2), although a recently deorphanized GPCR, GPR55, has 
been proposed as a putative cannabinoid receptor (Shore and Reggio, 2015). 
 
Both CB1 and CB2 predominantly couple to pertussis toxin-sensitive Gi/o proteins to inhibit 
adenylate cyclase, the enzyme responsible for the conversion of ATP into cAMP. 
However, CB1 under certain circumstances can couple to Gs proteins and activate 
adenylate cyclase (Turu and Hunyady, 2010). 
 
CB1 is primarily associated with the central nervous system (CNS) and predominantly 
located on presynaptic terminals of neurons within regions of the brain including the 
hippocampus, cerebral cortex, and cerebellum. Within these regions, activation of CB1, 
the most abundant and ubiquitous GPCR in the CNS, inhibits neurotransmitter release 
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via retrograde signaling mechanisms (Mikasova et al., 2008). Secondarily, CB1 is also 
located peripherally in the gastrointestinal tract, reproductive tract and endocrine tissue.  
 
CB2 is predominantly located in peripheral and immune tissue including hematopoietic 
cells such as lymphocytes, natural killer cells and macrophages. CB2 has also been 
characterized in neuroglial tissue of the central nervous system including resident 
macrophages of the brain, microglia, and is associated with inflammation (Amenta et al., 
2014). Furthermore, activation of CB2 has been implicated in dampening the replication 
of human immunodeficiency virus (HIV) in macrophages (Persidsky et al., 2015).  
 
1.5 Orthosteric Activation and Receptor States 
GPCRs are canonically activated via ligand binding at the orthosteric site, which is 
identified as the site of endogenous ligand binding. However, some receptor populations 
contain one or more additional, topographically distinct, sites for allosteric modulator 
binding. CB1 is one such receptor, containing at least one allosteric site. However, this 
work is primarily focused on orthosteric agonists of CB2, which does not have any known 
allosteric sites. 
 
Some GPCRs exhibit constitutive activity, such as the cannabinoid receptors. 
Constitutively active receptors are present in the active state without the presence of 
bound ligand, leading to a basal level 
of activity and downstream signaling. 
Receptor activity is differentially 
modified from the basal level by the 
binding of various orthosteric ligand 
types. Agonists promote the active 
conformation of the receptor to varying 
extents. Full agonists elicit a maximal 
biological response, while partial 
agonists cannot elicit as large an effect Figure 2. Differential levels of GPCR activation. 
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on the same receptors. Inverse agonists promote the inactive state of the receptor and 
reduce the number of receptors in the active conformation. Antagonists do not elicit a 
change in the receptor state and have no effect on signaling. Although antagonist binding 
blocks the orthosteric site, receptor activity remains at basal level.  
 
1.6 Cannabinoid Receptor Family Ligands 
The cannabinoid receptors bind three subclasses of classical neuromodulatory lipids: 
endocannabinoids, phytocannabinoids and synthetic cannabinoids. Ligands of all three 
subclasses are generally hydrophobic molecules that bind the orthosteric site of the 
receptor. 
 1.6.1 Endocannabinoids 
The endocannabinoids are endogenous omega-6 fatty acid-derived ligands produced in 
the brain. Along with the cannabinoid receptors, the endocannabinoids and the enzymes 
responsible for catalyzing reactions involved in their synthesis and degradation constitute 
the endocannabinoid system. The two major endocannabinoids are N-
arachidonoylethanolamine, or anandamide (AEA) and 2-arachidonoylglycerol (2-AG).  
 1.6.2 Phytocannabinoids 
Phytocannabinoids are plant-derived ligands. The major ligand of this class is Δ9-
tetrahydrocannabinol (Δ9-THC; derived from Cannabis sativa), the main psychoactive 
component of marijuana and a partial agonist of both CB1 and CB2. Cannabidiol (CBD) is 
another major phytocannabinoid derived from Cannabis sativa. CBD may bind to both 
CB1 and CB2, but at concentrations in the micromolar range, and is thus considered to 
possess low affinity for both receptors. In contrast to Δ9-THC, CBD is considered to be 
non-psychotrophic (Pertwee, 2008).  
 1.6.3 Synthetic Cannabinoids 
The third ligand subclass includes synthetic endocannabinoids, which are generally 
modified structures of endocannabinoids and phytocannabinoids optimized as potential 
small molecule drugs. CP55940 ((1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-
4-(3- hydroxypropyl)cyclohexan-1-ol) is a full agonist at both CB1 and CB2 with affinities 
in the low nanomolar range (i.e. < 5 nM).  SR141716A (5-(4-chlorophenyl)-1-(2,4-
dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide) is an 
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antagonist of CB1 that was clinically approved and marketed in Europe as the anti-obesity 
drug rimonabant. Within a few years of approval, the drug was withdrawn from the market 
due to psychiatric side effects including major depression, anxiety, and suicidal thoughts 
in patient populations (Erdozain et al., 2012).  
 
1.7 Putative Novel CB2 - Selective Agonists 
Commercially available putative cannabinoid receptor 2-selective agonists were identified 
as hits in a high throughput screen (HTS) from a library of approximately 40,000 
compounds. Receptor selectivity was assessed by using CHO-K1 cells transfected with 
CB2 relative to the null strain. Ligands were identified based on inhibition of cAMP 
accumulation. Previously synthesized for other purposes, these small molecules have 
been further assessed for their selectivity for CB2 and effects on downstream signaling in 
this study.  
 
ASX015283 (2-(7-oxo-2,3-dihydro-7H-furo[3,2-g]chromen-2-yl)propan-2-yl 2,4-
dichlorobenzoate; Figure 4A) is a modification of parent compound, felamidin (2-[(2S)-7-
oxo-2,3-dihydrofuro[3,2-g]chromen-2-yl]propan-2-yl benzoate; Figure 4B). ASX015283 
has been synthetically modified from felamidin with the addition of two chloro- 
substituents on the distal benzene ring. The parent compound, felamidin, was one of 
Figure 3. Chemical structures of cannabinoid receptor ligands: (A) 2-AG and (B) AEA are 
endocannabinoids, (C) $9-THC is a phytocannabinoid, and (D) CP55940 and (E) SR141716A are 
synthetic cannabinoids. The latter is an inverse agonist while all others shown are agonists. 
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2,000 biologically active compounds from The Spectrum Collection compound library by 
MicroSource Discovery Systems. Initial HTS of this library was performed for inhibitors of 
6-phosphogluconate dehydrogenase (6-PGD), an enzyme responsible for catalyzing the 
conversion of 6-phosphogluconate into ribulose 5-phosphate during the oxidative phase 
of the pentose phosphate pathway. Felamidin was found to be biologically active as a 6-
PGD inhibitor and shown to affect cancer cell metabolism in animal studies by inhibiting 
cell proliferation and tumor growth (Lin et al., 2015). Additionally, felamidin was found to 
inhibit tumor cell replication with an EC50 of 11.6 µM in a test for cytotoxicity against A549 
non-small cell lung cancer cells (Rosselli et al., 2009).  
 
 
CSC003141(4-(tert-butyl)-N-(2,2,2-trichloro-1-(4-methylpiperidin-1-yl)ethyl)benzamide; 
Figure 5A) was tested for inhibition of HIV-1 RNase in a fluorescence-based HTS, but 
found to be inactive. However, a structurally similar compound, 4-fluoro-N-[2,2,2-trichloro-
1-(4-morpholinyl)ethyl]-benzamide (Figure 5B), was identified from a compound library at 
The Scripps Research Institute Molecular Screening Center as biologically active in HTS 
of multiple class A rhodopsin-like GPCRs including the neuropeptide Y receptor Y1 (NPY-
Y1) and the human muscarinic cholinergic receptor (hM1). This small molecule differs 
from test compound CSC003141 in that a methyl group has been removed and an oxygen 
has been substituted into the heteroatom ring while a fluoro- substituent has replaced the 
bulky tert-butyl group. This compound was active as a NPY-Y1 antagonist, and such 
molecules have therapeutic implications in appetite and circadian rhythms (Ishii et al., 
2007).  It was also found to be a human muscarinic cholinergic hM1 agonist with clinical 
Figure 4. Chemical structures of (A) test compound ASX015283 (molecular weight: 419. 265 g/mol), 
and (B) parent compound, felamidin (molecular weight: 350.37 g/mol).  
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implications in the treatment of Alzheimer’s disease and schizophrenia (Matucci et al., 
2016). 
 
CMB038865 (1-(indoline-1-carbonyl)-4,7,7-trimethyl-2-oxabicyclo[2.2.1]heptan-3-one; 
Figure 6A) is structurally related to compound CHEMBL2338187 (PubChem ID; Figure 
6B) with an adamantane 
ring modification and 
agonist activity at CB2 
identified in cAMP and #-
arrestin recruitment 
assays (Nettekoven et 
al., 2013). 
 
CZ000026 (N2,N3-diphenylquinoxaline-2,3-diamine; Figure 
7) has been patented as a farnesoid X receptor (FXR) 
antagonist (Houze et al., U.S. Patent 7,511,043, 2009). FXR 
antagonists are potential therapeutics for the treatment of 
hypercholesterolemia.  By controlling the rate-limiting enzyme 
involved in metabolism of cholesterol to bile acids, cholesterol 
Figure 5. Chemical structures of test compound CSC003141 (molecular weight: 405.799 g/mol) (A), 
and structurally similar compound (4-fluoro-N-[2,2,2-trichloro-1-(4-morpholinyl)ethyl]-benzamide) that 
is biologically active as a GPCR class A ligand (B). 
Figure 6. Chemical structure of test compound CMB038865 (molecular 
weight: 299.37 g/mol) (A), and similar structure CHEMBL2338187 
(molecular weight: 267.372 g/mol) (B).  
Figure 7. Chemical structure of test 
compound CZ000026 (molecular weight 
312. 376 g/mol). 
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7 alpha-hydroxylase (CYP7A1), it is possible to modulate FXR-mediated gene expression 
(Sepe et al., 2016). 
  
! 9 
2. MATERIALS AND METHODS 
 
2.1 Compounds.   
Test compounds ASX01583 (2-(7-oxo-2,3-dihydro-7H-furo[3,2-g]chromen-2-yl)propan-2-
yl 2,4-dichlorobenzoate), CSC003141 (4-(tert-butyl)-N-(2,2,2-trichloro-1-(4-
methylpiperidin-1-yl)ethyl)benzamide), CMB038865 (1-(indoline-1-carbonyl)-4,7,7-
trimethyl-2-oxabicyclo[2.2.1]heptan-3-one), and CZ000026 (N2,N3-diphenylquinoxaline-
2,3-diamine) were obtained from Bristol-Myers Squibb (Wallingford, CT) as hits from high 
throughput screening conducted for CB2-selective agonists. Briefly, assays to assess 
inhibition of cAMP accumulation were performed in duplication using Chinese hamster 
ovary-K1 (CHO-K1) cells both expressing and lacking CB2, with the output of half maximal 
effective concentration (EC50) values. 10 mM stock concentrations of compound were 
prepared in dimethyl sulfoxide (DMSO) with particular attention to air exposure and were 
subsequently serially diluted. 
 
2.2 CB1 and CB2 Expression and Membrane Preparation.  
Human embryonic kidney 293T (HEK293T) cells (ATCC, Manassas, VA) were seeded at 
a density of approximately 1.0 × 106 cells per 100 mm dish in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 3.5 mg/ml 
glucose at 37°C in 5% CO2.  For transient expression of receptors, after approximately 
twenty-four hours, cells were transfected with 5-10 μg CB1 or CB2 cloned into pcDNA 3.1 
using the calcium phosphate precipitation method (Chen and Okayama, 1987) or 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Approximately twenty-four hours post-
transfection, cells were harvested and washed twice with phosphate-buffered saline 
(PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,1.8 mM KH2PO4, pH 7). After 
resuspension in PBS supplemented with mammalian protease inhibitor cocktail 
containing 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatin A, E-64, 
bestatin, leupeptin, and aprotinin (Sigma, St. Louis, MO), cells were lysed via nitrogen 
cavitation under 750 psi for 5 min using a Parr cell disruption bomb. In a two-step 
centrifugation, lysate was spun at 500×g for 10 min at 4°C and collected supernatant was 
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spun at 13,000 RCF for 40 min at 4°C. Post-ultracentrifugation, the membrane-containing 
pellet was resuspended in TME buffer (25mM Tris-HCl, 5 mM MgCl2, and 1 mM EDTA, 
pH 7.4) containing 7% sucrose (w/v). The Bradford assay (Bradford, 1976) was used to 
determine protein concentration. Membrane aliquots were stored at -80°C until use.  
 
2.3 Saturation Radioligand Binding.  
At least nine concentrations of radiolabeled ligand (typically ranging from 0.23 nM to 
37.60 nM) were used to determine Bmax and Kd values of the receptors. 5 μg of membrane 
was incubated at 30°C for 60 min in a total assay volume of 200 μl TME buffer containing 
0.1% fatty acid-free bovine serum albumin (BSA) using [3H]CP55940 (150.2 Ci/mmol, 
Perkin Elmer Life Sciences, Boston, MA). Nonspecific binding was determined with 1 μM 
unlabeled CP55940. 
 
2.4 Radioligand Binding.  
In heterologous competition binding experiments to determine Ki values of the receptor 
for the compound, 5-10 μg of CB1 or CB2 membrane were incubated for 60 min at 30°C 
with [3H]CP55940 (150.2 Ci/mmol, Perkin Elmer Life Sciences, Boston, MA) at 1.5 nM, 
near the Kd value determined from saturation binding isotherms, in a total assay volume 
of 200 μl of TME buffer containing 0.1%  BSA. Binding assays were performed using nine 
concentrations of unlabeled competitor test compound, typically from 100 pM to 100 µM. 
Unlabeled CP55940 at a concentration of 1 μM was used to determine nonspecific 
binding. Reactions were terminated upon addition of 300 μl TME buffer containing 5% 
BSA and filtration with a Brandel cell harvester through Whatman GF/C filter paper 
(Brandel, Gaithersburg, MD). Radioactivity trapped in filters was measured via liquid 
scintillation counting. When possible, total assay volume and amount of membrane were 
adjusted to avoid ligand depletion by keeping total bound ligand less than 10%. 
 
2.5 Guanosine 5’-O-(3-Thio)Triphosphate (GTP!S) Binding.  
In [35S]GTPγS binding experiments, 8 μg of CB2 membrane were incubated for 60 min at 
30°C in a total assay volume of 200 μl of GTPγS binding buffer (50 mM Tris-HCl, pH 7.4, 
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3 mM MgCl2, 0.2 mM EGTA, and 100 mM NaCl) with nine concentrations of test 
compound, 0.1 nM [35S] GTP!S (1250 Ci/mmol, Perkin Elmer Life Sciences, Boston, MA), 
10 μM GDP, and 0.1% (w/v) BSA. Unlabeled GTP!S at a concentration of 10 μM was 
used to determine nonspecific binding. Reactions were terminated via Whatman filtration. 
Bound [35S]GTP!S trapped in filters was determined by liquid scintillation counting. 
 
2.6 Immunoblotting Studies for ERK1/2 Phosphorylation. 
HEK293T cells seeded in 6-well plates at a density of 2.0 × 105 cells per well and 
transiently expressing CB1 or CB2 were treated with 10 ng/mL pertussis toxin (PTX) (EMD 
Millipore Corporation, Billerica, MA) to abrogate Gi/o protein signaling at 37°C prior to 
compound treatment. After 16 hours, cells were exposed to test compounds diluted in 
Gibco Opti-MEM reduced serum medium (Thermo Fisher Scientific, Rockford, IL) 
supplemented with 0.1% FBS for 5 minutes. Cells were then washed in ice-cold lysis 
buffer containing 150 mM NaCl, 1.0% IGEPAL CA-360, 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris, pH 7.5, and protease inhibitor cocktail. Cell lysates were centrifuged at 
18,000 RCF for 15 min at 4°C. After heating for 3 min at 95°C, 13 μg of total protein 
samples were resolved by 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) run at 120V and were subsequently transferred to 
polyvinylidene fluoride (PVDF) membranes. After overnight incubation with SuperBlock 
T20 PBS blocking buffer (Fisher Scientific, Pittsburgh, PA), the membranes were 
incubated at RT with primary antibody (1:3000 anti-rabbit phospho-p44/42; Cell Signaling 
Technology, Danvers, MA) for 1 hour, then were washed with Tween-TBS (10X TBS and 
0.1% Tween) for 10 min per wash for a total of three washes at RT. After secondary 
incubation with 1:6000 goat anti-rabbit peroxidase-conjugated antibody (Cell Signaling 
Technology, Danvers, MA) for 1 hour at RT on an orbital shaker, specific immunoreactivity 
was visualized using the Supersignal West Femto Chemiluminescent Substrate System 
(Thermo Fisher Scientific, Rockford, IL).  
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2.7 Data Analysis and Image Quantification.  
All radioligand binding assays were carried out in triplicate (duplicate in parallel), with data 
presented as the mean ± SE value or the mean with corresponding 95% confidence limits 
from at least three independent experiments except when no binding was detected 
reproducibly. Kd and Bmax values were calculated by nonlinear regression fitted to a one 
binding site model using GraphPad Prism 5.04 (GraphPad Software, La Jolla, CA). Ki 
values were calculated using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) 
based on Kd values obtained from saturation binding isotherms.  
 
Immunoreactive bands of phospho-ERK1/2 were quantified using the gel analysis tool in 
the open source software ImageJ/FIJI (National Institutes of Health, Bethesda, MD; 
https://imagej.nih.gov/ij/). pERK 1/2 band intensities are expressed as mean fold change 
over DMSO treatment for two independent experiments. A representative image is 
shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
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3. RESULTS 
 
Chemical structures of test compounds pursued in greater detail at the molecular and 
cellular levels are summarized in Figure 8.  
 
3.1 Saturation binding isotherms.  
Multiple saturation assays were performed throughout the experimental process of 
assessing test compound affinity for CB1 and CB2. Stoichiometry of receptor to G protein 
must be ensured upon creation of each new membrane preparation. Additionally, 
saturation binding assays serve as a preliminary measure to verify membrane preparation 
functionality and quality. Bmax and Kd values are parameters of saturation binding 
isotherms. While Bmax provides the maximum number of binding sites, Kd, the equilibrium 
binding constant, or concentration of ligand that is required to obtain half-maximum 
ASX015283
A
CSC003141
*
B
CMB038865
*
C
CZ000026
D
Figure 8. Putative CB2-selective agonists. (A) ASX015283, (2-(7-oxo-2,3-dihydro-7H-furo[3,2-g]chromen-2-yl)propan-2-yl 
2,4-dichlorobenzoate), MW 419.265 g/mol,  (B) CSC003141, (4-(tert-butyl)-N-(2,2,2-trichloro-1-(4-methylpiperidin-1-yl)ethyl)
benzamide), MW 405.799 g/mol, (C) CMB038865, (1-(indoline-1-carbonyl)-4,7,7-trimethyl-2-oxabicyclo[2.2.1]heptan-3-one), 
MW 299.370 g/mol, and (D) CZ00026, (N2,N3-diphenylquinoxaline-2,3-diamine), MW 312.376. * denotes chiral center.
*
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binding of the receptor at equilibrium, indicates the affinity of the receptor for the 
radioligand [3H]CP55940. A representative saturation binding assay performed with CB2 
membrane preparation is shown in Figure 9. 
 
3.2 ASX015283 and CSC003141 
exhibit preferential binding to 
CB2. 
Based on heterologous competition 
binding experiments using 
radiolabeled [3H]CP55940, test 
compounds ASX015283 and 
CSC003141 bind preferentially to 
CB2 over CB1. No concentration-
dependent binding to CB1 was 
detected up to 1 µM for both 
ASX015283 and CSC003141(Figures 10A and 11A).   
 
For CB2, as the concentration of ASX015283 and CSC003141 increases, these test 
compounds, ASX015283 and CSC003141, are able to outcompete radiolabeled 
CP55940 for the orthosteric binding site on CB2, eliciting a decrease in specific binding 
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Figure 9.  The equilibrium dissociation constant, Kd = 1.4 nM, 
of the known CB2 agonist [3H]CP55940 was directly determined 
in a saturation binding assay.  Data is shown as mean of one 
independent experiment (duplicates performed in parallel). 
Figure 10. ASX015283 does not bind CB1 up to 1 μM (A), however it binds CB2 with Ki = 147 nM (B), as determined 
by competition radioligand binding assays against known agonist [3H]CP55940.  Data is depicted as the mean of three 
independent experiments, each performed in duplicate. 
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of CP55940. However, ASX015283 binds CB2 with marginally stronger affinity compared 
to CSC003141 (i.e. ~1.6-fold; compare Figures 10B and 11B). ASX015283 binds CB2 
with an equilibrium dissociation constant Ki = 147 nM compared to CSC003141, with Ki = 
242 nM. The difference in affinity between the two compounds is telling, however, not 
statistically significant. Since there is no CB1 binding for these compounds, these 
compounds have a stronger binding affinity for CB2 rather than CB1. Therefore, 
ASX015283 and CSC003141 are selective for CB2. Due to enhanced receptor subtype 
preference, these compounds were pursued further by assessing G protein coupling in 
GTP!S binding assays (refer to section 3.5). 
 
3.3 CMB038865 exhibits nearly 100X selectivity for CB1.  
Heterologous competition binding assays using radiolabeled [3H]CP55940 with 
competitor test compound CMB038865 reveal that while CMB038865 does bind CB2, it 
is approximately 100-fold more selective for CB1.  
 
CMB038865 binds to CB2 in the high nanomolar range, with a Ki = 903 nM. CMB038865 
binds to the CB2 receptor with less potency compared to the interaction at CB1. Although 
CMB038865 is a weak agonist for CB2, it is not selective for the receptor, since 
CMB038865 also detectably binds CB1. Binding to CB1 is a higher affinity interaction, with 
Ki = 10 nM when analysis was done using the one site fit model. However, an increase in 
Figure 11. CSC003141 does not bind CB1 up to 1 μM (A), however it binds CB2 with Ki = 242 nM (B) as determined 
by competition radioligand binding assays against known agonist [3H]CP55940.  Data is depicted as the mean of three 
independent experiments, each performed in duplicate. 
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specific binding of [3H]CP55940, indicative of enhanced receptor activation, is consistent 
with that expected of positive allosteric modulation.   Given the distinct and unexpected 
shape of the CB1 binding curve with CMB038865 (Figure 12A), a one site binding model 
is inappropriate. An allosteric modulator titration model for the curve provides a KB of 35 
nM and " of 2.3.  
 
 
3.4 CZ000026 does not exhibit receptor subtype selectivity. 
Heterologous competition binding experiments with radiolabeled [3H]CP55940 were 
performed with test compound CZ000026. CZ000026 has low affinity for both CB1 and 
CB2, binding both receptors in the micromolar range. The equilibrium dissociation 
constant for CB1 binding, Ki = 1.8 µM (1798 nM), is indicative of a weak binding 
interaction. The compound binds to CB2 with similar affinity, with Ki = 1.1µM (1097 nM).  
Compared to test compounds ASX015283, CSC003141, and CMB038865, which are 
selective for either CB1 or CB2, CZ000026 is neither selective nor particularly potent at 
either receptor. All binding data for these test compounds is summarized in Table 1.  
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Figure 12. CMB038865 binds CB1 with a KB= 35 nM and ɑ = 2.3,  (A), and CB2 with a Ki = 903 nM (B), as determined 
by competition radioligand binding assays against known agonist [3H]CP55940.  Data is depicted as the mean of three 
independent experiments, each performed in duplicate. 
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3.5 Dose-dependent GTP!S binding is elicited by all test compounds.  
[35S]GTP!S radioligand binding assays were performed on all test compounds to evaluate 
G protein coupling activity as a result receptor activation elicited by test compound 
binding. This functional assay monitors G protein activation by determining the extent of 
binding nonhydrolyzable GTP analog to G" subunits. G protein activation was initially 
implicated in inhibition of cAMP accumulation assays conducted by Bristol-Myers Squibb, 
with EC50 values shown in Table 2, as expected for a Gi coupled GPCR. Additionally, 
three of the four compounds are agonists at CB2, albeit to varying extents of agonism, 
with binding affinities summarized in Table 1.  
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Figure 13. CZ000026 binds CB1 with Ki = 1796 nM (A), and CB2 with Ki = 1097 nM (B), as determined by competition 
radioligand binding assays against known agonist [3H]CP55940.  Data is depicted as the mean of three independent 
experiments, each performed in duplicate. 
Table 1. Test compound binding to CB1 and CB2 using [3H]CP55940 as a tracer.
Ki (nM)
KB (nM) ɑ CB1 CB2
ASX015283* N.B.a 147
CSC003141* N.B.a 242
CMB038865* 35 2.3 “10” 903
CZ000026 1796 1097
a no binding detected up to 1 μM
* enantiomeric mixture
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All four test 
compounds elicited 
a dose-dependent 
increase in specific 
GTP!S binding 
upon activation of 
CB2, with EC50 
values in the 
nanomolar range. 
ASX015283 robustly activated G protein coupling, with EC50 = 57 nM. CSC003141 also 
caused an increase in activated G protein binding, with EC50 = 78 nM. CMB038865 had 
an EC50 = 105 nM. Test compound CZ000026 was least effective at eliciting the dose-
dependent increase in specific GTP!S binding, with an EC50 value of 620 nM.  In general, 
test compounds ASX015283, CSC003141, and CMB038865 were more efficacious in 
their ability to activate G protein subunits compared to CZ000026. These data are 
summarized in Table 2.  
 
3.6 Extracellular signal-regulated kinase phosphorylation studies. 
Two test compounds, ASX015283 and CMB038865, with high affinity for CB2 or CB1 
respectively, were pursued further to assess downstream signaling via the mitogen-
activated protein kinase (MAPK) pathway as measured by the phosphorylation of 
isoforms of extracellular signal-regulated kinase (ERK). 
 
ERK was selected to assess downstream signaling due to its robust signal upon 
compound-induced receptor activation. This high signal, along with spatiotemporal 
factors, facilitates the differentiation of G protein or #-arrestin-mediated signaling. To 
confirm Gi/o protein-dependent ERK phosphorylation, pertussis toxin (PTX) was used to 
abrogate Gi/o and determine if that diminishes downstream phosphorylation of ERK. PTX 
blocks G protein signaling via Gi, resulting in lower levels of ERK phosphorylation, as 
shown in Figures 15 and 17.  
Table 2. [35S]GTPγS binding of test compounds at CB2.
EC50 (nM)
Ligand cAMPa GTPγSb
ASX015283* 73 57
CSC003141* 29 78
CMB038865* 45 105
CZ000026 45 620
a inhibition of cAMP accumulation in high throughput screens; b binding of radiolabeled [35S]
GTPγS;* enantiomeric mixture. 
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ASX015283 induces robust ERK phosphorylation. At a 0.1 μM concentration of 
ASX015283, ERK phosphorylation was nearly 12-fold higher than basal level DMSO 
treatment (Figure 15). This concentration of ASX015283 provided the highest level of 
ERK phosphorylation and therefore is the optimal effective concentration of the test 
compound for treatment with minimal cytotoxicity. Since treatment with test compound 
ASX015283 in the presence of PTX abrogated ERK phosphorylation, ASX015283 
initiates Gi/o protein-dependent phosphorylation of this downstream kinase.  
 
CMB038865, with nearly 100-fold selectivity for CB1 over CB2, also engages in robust 
phosphorylation of ERK. However, robust phosphorylation is only induced by CB2 
activation. In CB1-expressing cells, PTX does not affect CMB03885-induced ERK 
phosphorylation (Figure 16) and levels of ERK phosphorylation are low across both 
concentrations of test compound. However, in CB2-expressing cells, PTX significantly 
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Figure 15. ASX015283-induced ERK1/2 
phosphorylation in cells expressing CB2. (A) pERK 
is substantially reduced with pertussis toxin (PTX) 
treatment.  Total ERK1/2 is a control and is constant.
(B) Quantification of A. Data is representative of one 
independent experiment, quantified as band intensity. 
Light bars indicate phosphorylation in the presence of 
PTX, while dark bars indicate phosphorylation in the 
absence of PTX. 
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reduces ERK signal to nearly basal levels.  At a 0.5 μM concentration of CMB038865 in 
cells expressing CB2, ERK phosphorylation levels are approximately 100-fold higher than 
basal level (Figure 17).  Given the binding affinity for CMB038865 at CB2 (Ki = 903 nM), 
this level of phosphorylation is particularly remarkable considering this concentration of 
test compound elicits less than half receptor occupancy. All binding and downstream 
signaling data for these test compounds are summarized in Table 3.  
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Figure 16. CMB038865-induced ERK phosphorylation in cells 
expressing CB1. (A) pERK is not abrogated with pertussis toxin 
(PTX) treatment. (B) Quantification of A. Data is representative of 
two independent experiments,  quantified as band intensity. Light 
bars indicate phosphorylation in the presence of PTX, while dark 
bars indicate phosphorylation in the absence of PTX.
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Figure 17. CMB038865-induced ERK phosphorylation in cells 
expressing CB2. (A) Pertussis toxin (PTX) substantially abrogates 
CMB038865-induced ERK1/2 phosphorylation.  (B) Quantification 
of A. Data is representative of two independent experiments, 
quantified as band intensity. Light bars indicate phosphorylation in 
the presence of PTX, while dark bars indicate phosphorylation in 
the absence of PTX. 
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Table 3.  Summary of radioligand binding, GTPγS binding, and ERK phosphorylation studies.
Ki (nM)
GTPγS binding 
EC50  (nM)
PTX-sensitive 
ERK phosphorylation
Ligand CB1 CB2 CB2 CB1 CB2
ASX015283* N.B.a 147 57 N.D.b +
CSC003141* N.B.a 242 78 N.D.b N.D.b
CMB038865* 10c 903 105 - ++
CZ000026 1796 1097 620 N.D.b N.D.b
* enantiomeric mixture; a No binding detected up to 1 μM; b Assay not done for the indicated ligand and receptor combination; c One site fit binding 
model (allosteric model provides Kb = 35 nM.)
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4. DISCUSSION 
 
These data indicate that of the four structurally distinct putative CB2-selective agonists 
investigated in this study, ASX015283 and CSC003141 are selective agonists of CB2 that 
do not detectably interact with CB1 up to 1 µM.  ASX015283 is more potent than 
CSC003141 at binding the orthosteric site of CB2. However, while the ~ 1.6-fold difference 
between the binding affinity at CB2 for these two compounds (Ki = 147 nM vs. 242 nM) is 
telling, it is not statistically significant (p = 0.100), as determined by the Mann-Whitney 
non-parametric t-test (Mann and Whitney, 1947).   
 
As a result of their activation of CB2, these compounds also are effective at inducing 
receptor coupling to G protein subunits. ASX015283, the compound with the strongest 
affinity interaction at the CB2 receptor level and most potent inducer of G protein coupling 
(Figure 14A), engages in downstream signaling as determined by 5-minute test 
compound-induced PTX-sensitive phosphorylation of ERK ½ isoforms.  
 
CZ00026 binds both receptors with weak affinity within the micromolar range.  Therefore, 
CZ00026 is a non-preferential weak agonist of CB1 and CB2. Despite weak binding 
affinity, this compound sufficiently activates CB2 to induce G protein coupling within the 
nanomolar range as determined by GTP!S assays. However, due to lack of receptor 
subtype selectivity and weak binding affinity, this compound will not be pursued in further 
studies.  
 
CMB038865 binds CB2 at high nanomolar (Ki = 903 nM) affinity, indicating a relatively 
weak binding interaction of the test compound with the receptor. Surprisingly, in 
competition radioligand binding assays, CMB038865 binds CB1 with strong affinity (Ki = 
10 nM; KB = 35 nM) but does not inhibit CP55940 binding as expected of an agonist. 
Rather, CMB038865 enhances specific binding of CP55940 in a dose-dependent 
manner. This finding is consistent with that of positive allosteric modulation.  A plausible 
mechanism is that CMB038865 acts at a topographically distinct allosteric site on CB1 to 
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enhance the binding of the ligand at the orthosteric site. Therefore, CMB038865 is a weak 
agonist at CB2, and a putative PAM for CB1.  These suspected properties of CMB038865 
make it a rare addition to the pharmacological toolkit available to the field.  
 
Activation of CB2 by CMB038865 resulted in receptor coupling of G protein subunits as 
determined by GTP!S binding assays. Additionally, CMB038865 induced robust ERK 
phosphorylation in cells expressing CB2, with a nearly 100-fold increase over vehicle 
treatment.  This is remarkable in terms of efficacy since at a concentration of 0.5 µM, 
robust ERK ½ phosphorylation was elicited with less than half receptor occupancy. PTX 
markedly diminishes ERK signal in CB2 expressing cells, but not in CB1- expressing cells. 
Upon CMB038865-induced activation of CB1, ERK phosphorylation levels remain 
consistently low regardless of the presence of PTX.  To ensure that these results were 
not due to the presence of CMB038865 as a metabolite, new drug stocks were prepared 
before each experiment. As PTX abrogates Gi/o signaling, it is plausible that this 
compound engages in alternative downstream signaling mechanisms when interacting 
with CB1 or does not go through ERK pathways.  
 
As chronic pain remains a common affliction of American adults, drug discovery efforts 
have shifted priority to an avenue of non-addictive, non-opioid analgesic and anti-
inflammatory agents.  By selectively targeting CB2, analgesia is possible without the 
psychoactive effects of CB1 activation in the central nervous system. However, achieving 
receptor subtype selectivity is a pharmacological feat, given that the orthosteric binding 
site is largely conserved across cannabinoid receptor subtypes. ASX015283 and 
CSC003141 are able to surmount this difficulty by selectively targeting CB2.  
 
Due to the enantiomeric nature of both CB2-selective compounds, ASX015283 and 
CSC003141, as well as the putative CB1 PAM CMB038865, separation of the compounds 
into individual enantiomers would be of potential clinical benefit.  Enantiopure forms of 
compounds have been shown to potentially act antagonistically towards each other. One 
novel allosteric modulator for CB1, GAT211, when separated into its chiral forms had 
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agonist activity in the R-(+)-enantiomer (GAT 228) and PAM activity with the S-(-)-
enantiomer (GAT 229) (Laprairie et al., 2017). Separation of test compounds into 
enantiomeric forms will be pursued via asymmetric synthesis or chiral chromatography.  
Enantiopure compounds will then be characterized using these assays and others if they 
show promise in initial screens.  
 
Once enantiopure forms have been obtained, to further pursue these leads, structure-
activity relationship studies will be conducted on ASX015283, the compound with 
strongest affinity for CB2 within the nanomolar range, as well as the putative PAM, 
CMB038865. Modifications to the structural scaffolds will be performed by collaborator of 
the Kendall laboratory, Dr. Dai Lu of Texas A&M Rangel College of Pharmacy, to enhance 
the binding affinity of the test compound to CB2 within lower nanomolar or optimally sub-
nanomolar ranges.  
 
Additionally, an interesting pursuit for these compounds would be to obtain a holistic 
phosphorylation profile. Future studies will include measuring levels of phosphorylation 
of other kinases, including Src and Jnk. To assess analgesic and anti-inflammatory 
properties of these compounds, studies examining the levels of mRNA expression of CB2 
in addition to other markers of pain, as well as patterns in immune cell migration, and 
animal studies will be performed.  
 
In summary, the chief finding of this study is that ASX015283 and CSC003141 are CB2-
selective orthosteric agonists with reasonably high affinity. While CMB038865, a weak 
agonist at CB2, binds to CB1 with at least 100-fold enhanced binding affinity, and is 
consistent with a positive allosteric modulator acting at CB1 due to its ability to increase 
specific binding of orthosteric ligand CP55940.  
 
The pharmacological profile of ASX015283 and CSC003141 as receptor subtype 
selective compounds offers promising potential therapeutic advantages in the case of 
treating chronic pain and inflammatory conditions. These leads serve as the starting point 
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for the development of small molecule agonists with enhanced potency at CB2 for optimal 
analgesic and anti-inflammatory effects in the absence of psychotrophic interactions.  
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